JUN 17, 2021 11:00 AM PDT

Humoral response after SARS-CoV-2 mRNA vaccine in a cohort of hemodialysis patients and kidney transplant recipients

Sponsored by: DiaSorin
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Senior Medical Virologist in the University Hospital of Limoges, France. Head of the department of infectious serologies. Deputy Director of the National Reference Centre for Herpesviruses
    BIOGRAPHY

Abstract

Date:  June 17, 2021

Time: 11:00am PDT, 8:00pm CET

 

BACKGROUND Kidney transplant recipients and patients on hemodialysis are immunocompromised populations excluded from vaccine trials. Data are lacking regarding their humoral response to COVID vaccination. METHODS We investigated early serological response after COVID 19 vaccination with Pfizer/BioNTech (BNT162b2) mRNA vaccine in 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls. Antibody titers against SARS-CoV-2 were measured at 0, 14, 28, 36 and 58 days after the first injection. RESULTS In controls, antibodies were detected at a positive level (>13 AU/ml) at day 14 post-injection, and increased progressively, to peak at day 36 (1082 AU/mL [IQR: 735.0-1662]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/mL [IQR 83.4-526.0]. A positive antibody level was detected in only 3 kidney transplant recipients. In hemodialysis patients, age, serum albumin and Kt/V were positively correlated with serological response (p< 0.043 and p<0.019 respectively); non responders to HBV vaccine had the lowest titers of anti-SARS-CoV-2 antibodies. CONCLUSIONS Our results suggest that the post-vaccine humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, while it is lowered by the uremic condition in patients undergoing hemodialysis.

 

Learning Objectives

  • Evaluate the humoral response after SARS-CoV-2 mRNA vaccine in a setting of fragile individuals
  • To assess the performance of serology assay in post vaccination monitoring of fragile individuals
  • To evaluate the clinical impact of serology test in monitoring humoral response of fragile individuals

 

 

Webinars will be available for unlimited on-demand viewing after live event.

 

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


Show Resources
You May Also Like
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
SEP 28, 2022 9:00 AM PDT
SEP 28, 2022 9:00 AM PDT
Date: September 28, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) While COVID-19 continues to be the most pressing diagnostic focus for clinical laboratories, HIV remains a serious g...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
Loading Comments...
Show Resources